Drug Trial Radar · NCT07772492
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Mar 2032
Study completion Mar 2032
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body. Some treatment options are available for adults and adolescents with AA, however there is still high unmet need for systemic treatments (treatment that moves throughout the bloodstream) approved for young patients with AA. Treatments may not work for all patients or may stop working over time. Because of this, researchers are developing new AA treatments, like upadacitinib. Upadacitinib is a type of medicine called a Janus- Kinase (JAK) inhibitor and works with the body to fight the inflammation that can cause AA. In this study, different doses (amounts) of upadacitinib are being compared to treatment with placebo (looks like the study treatment but contains no medicine). Upadacitinib is an investigational JAK inhibitor being developed for the treatment of severe alopecia areata in pediatric patients. This is a randomized, double-blind, placebo-controlled study. Participants are placed in 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. Pediatric participants with a diagnosis of severe alopecia areata with SALT score ≥ 50 scalp hair loss will be enrolled. Participants will be at least 6 years old at Screening and less than 18 years old at Baseline. Approximately 300 participants will be enrolled in the study at approximately 120 sites worldwide. Participants will receive oral doses of upadacitinib or matching placebo daily, or twice daily, for approximately 160 weeks. The study comprises a 35-day Screening Period, a 24-week placebo-controlled double-blinded treatment period (Period A), a 28-week blinded extension treatment period (Period B), a 108-week blinded long-term extension period (Period C), and a 30-day follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Severe Alopecia Areata
Interventions
UpadacitinibDrug
Oral
PlaceboDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20, defined as less than or equal to 20% scalp hair loss.Time frame: At Week 24
- Number of Participants with Adverse Events (AEs)Time frame: Up to Week 160
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
Dermatology Research Associates - Los Angeles /ID# 282821
Los Angeles, California · Recruiting
Pediatric Skin Research - Miami /ID# 283281
Miami, Florida · Recruiting
Ada West Research /ID# 283063
Meridian, Idaho · Recruiting
Dawes Fretzin- Indianapolis /ID# 283498
Indianapolis, Indiana · Recruiting
Washington University School of Medicine - St. Louis /ID# 282819
St Louis, Missouri · Recruiting
Skin Specialists /ID# 283358
Omaha, Nebraska · Recruiting
Red River Research Partners - Fargo /ID# 283517
Fargo, North Dakota · Recruiting
Dermatologists of Southwestern Ohio (DSWO) /ID# 282818
Fairborn, Ohio · Recruiting
3A Research - East location /ID# 283404
El Paso, Texas · Recruiting
Texas Dermatology and Laser Specialists /ID# 282813
San Antonio, Texas · Recruiting
Virginia Clinical Research /ID# 283797
Norfolk, Virginia · Recruiting
Fundacion Respirar /ID# 283582
Buenos Aires, Argentina · Recruiting
Premier Dermatology - Kogarah /ID# 283484
Kogarah, New South Wales, Australia · Recruiting
Cornerstone Dermatology - Coorparoo /ID# 284160
Coorparoo, Queensland, Australia · Recruiting
Sinclair Dermatology - Melbourne /ID# 283854
East Melbourne, Victoria, Australia · Recruiting
Nagomi Dermatology Clinic /ID# 282713
Ebina-shi, Kanagawa, Japan · Recruiting
Shinsaibashi Inui Dermatology Clinic. /ID# 282706
Osaka, Osaka, Japan · Recruiting
Kyorin University Hospital /ID# 282702
Mitaka-shi, Tokyo, Japan · Recruiting
Clinical Trials New Zealand /ID# 283489
Hamilton, Waikato Region, New Zealand · Recruiting
Chungang University Hospital /ID# 282799
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
National Taiwan University Hospital /ID# 282895
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital /ID# 282900
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.